Good Efficacy With SB's Famvir
SmithKline Beecham's Famvir (famciclovir) has proved effective in the treatment of chronic hepatitis B, according to results from a double-blind, dose-ranging study involving 333 patients.
The patients, from 14 countries, selected because they were difficult to treat, were randomized to receive either famciclovir (500mg, 250mg or 125mg) or placebo for a period of 16 weeks.
"Famciclovir treatment resulted in a rapid, dose-dependent suppression of hepatitis B virus replication," said Christian Trepo from the Liver Unit, Hotel Dieu, France. He added that, "in all famciclovir-treated groups, the effect of hepatitis B virus DNA levels was evident within one week of therapy and was maintained throughout the 16-week treatment period."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze